Pharsight

Mitosol patents expiration

Can you believe MITOSOL received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9539241 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
Jan, 2028

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8186511 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
Jul, 2026

(2 years from now)

US9205075 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
Jul, 2026

(2 years from now)

US7806265 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
Feb, 2029

(4 years from now)

US9649428 MOBIUS THERAP Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
May, 2029

(4 years from now)

Mitosol is owned by Mobius Therap.

Mitosol contains Mitomycin.

Mitosol has a total of 5 drug patents out of which 0 drug patents have expired.

Mitosol was authorised for market use on 07 February, 2012.

Mitosol is available in for solution;topical dosage forms.

Mitosol can be used as mitosol is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery. it is intended for topical application to the site of glaucoma filtration surgery.

The generics of Mitosol are possible to be released after 21 May, 2029.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-21) Feb 07, 2019
Orphan Drug Exclusivity(ODE) Feb 07, 2019

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using MITOMYCIN ingredient

Market Authorisation Date: 07 February, 2012

Treatment: Mitosol is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery. it is intended for topical application to the site of glaucoma filtration surgery

Dosage: FOR SOLUTION;TOPICAL

More Information on Dosage

MITOSOL family patents

Family Patents